by Desiree Cobb-Olori | Mar 1, 2019
Leahy E Drug Development & Delivery March 2019 Vol 19 No 2: 46-49. At the recent American College of Neuropsychopharmacology (ACNP) meeting, Sunovion Pharmaceuticals and PsychoGenics Inc. announced positive Phase 2 results for SEP-363856, a novel, first-in-class...
by Desiree Cobb-Olori | Sep 26, 2015
doi: 10.1371/journal.pone.0134572. eCollection 2015. Brunner D., Kabitzke P., He D., Cox K., Thiede L., Hanania T., He D., Sabath E., Alexandrov V., Saxe M., Peles E., Mills A., Spooren W., Ghosh A., Feliciano P., Benedetti M., Clayton AL., Biemans B. PLoS One 2015...
by Desiree Cobb-Olori | Mar 5, 2015
Alexandrov V, Brunner D, Hanania T, Leahy E European Journal of Pharmacology.750 2015 82-89 DOI: 10.1016/j.ejphar.2014.11.047 Drug testing with traditional behavioral assays constitutes a major bottleneck in the development of novel therapies. PsychoGenics developed...
by Desiree Cobb-Olori | Oct 25, 2012
Zhang HK, Eaton JB, Yu LF, Nys M, Mazzolari A, van Elk R, Smit AB, Alexandrov V, Hanania T, Sabath E, Fedolak A, Brunner D, Lukas RJ, Vistoli G, Ulens C, Kozikowski AP. J.Med. Chem., 2012 55(18), pp 8028-8037
